Marshall Wace’s Rockwell Medical RMTI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-17,378
Closed -$148K 3332
2025
Q2
$148K Sell
17,378
-15,982
-48% -$163K ﹤0.01% 2500
2025
Q1
$377K Sell
33,360
-26,276
-44% -$477K ﹤0.01% 2185
2024
Q4
$1.22M Buy
59,636
+8,769
+17% +$256K ﹤0.01% 1646
2024
Q3
$2.02M Buy
+50,867
New +$1.37M ﹤0.01% 1363
2024
Q2
Sell
-9,783
Closed -$162K 2892
2024
Q1
$162K Sell
9,783
-7,727
-44% -$112K ﹤0.01% 2261
2023
Q4
$331K Sell
17,510
-6,680
-28% -$125K ﹤0.01% 1858
2023
Q3
$503K Buy
24,190
+22,579
+1,402% +$686K ﹤0.01% 1727
2023
Q2
$87.9K Buy
+1,611
New +$49.5K ﹤0.01% 2335
2021
Q4
Sell
-383
Closed -$25K 4228
2021
Q3
$25K Buy
+383
New +$29.1K ﹤0.01% 2952
2020
Q2
Sell
-369
Closed -$83K 1882
2020
Q1
$83K Buy
+369
New +$105K ﹤0.01% 1355
2019
Q2
Sell
-91
Closed -$57K 1759
2019
Q1
$57K Buy
+91
New +$41.5K ﹤0.01% 1514
2015
Q1
Sell
-849
Closed -$960K 920
2014
Q4
$960K Buy
849
+548
+182% +$562K 0.01% 572
2014
Q3
$302K Buy
301
+238
+378% +$269K ﹤0.01% 709
2014
Q2
$83K Sell
63
-71
-53% -$85.4K ﹤0.01% 899
2014
Q1
$187K Buy
+134
New +$174K ﹤0.01% 738

Other funds holding RMTI

Marshall Wace's RMTI Position: Q3 2025 in Review

Marshall Wace sold out of Rockwell Medical (RMTI) in Q3 2025, closing a stake of 17,378 shares — an estimated $148K sold.

Marshall Wace first reported a position in RMTI in Q1 2014 and held it in 15 quarters. The position peaked at $2.02M in Q3 2024. 36 funds tracked by Wall St. Rank hold RMTI as of Q3 2025.

  • Marshall Wace reported no remaining Rockwell Medical position as of Q3 2025 after selling out during the quarter.
  • Marshall Wace sold 17,378 Rockwell Medical shares in Q3 2025, an estimated $148K.
  • Marshall Wace first reported a position in Rockwell Medical in Q1 2014 and held it in 15 quarters.
  • Marshall Wace's Rockwell Medical position peaked at $2.02M in Q3 2024.
  • 36 funds tracked by Wall St. Rank held Rockwell Medical as of Q3 2025.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.